Universität zu Köln

Borchmann, Sven and von Tresckow, Bastian (2017). Novel agents in classical Hodgkin lymphoma. Leuk. Lymphoma, 58 (10). S. 2275 - 2287. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Classical Hodgkin lymphoma (cHL) is the most common hematological malignancy in young adults and can be cured in most cases. However, relapsed and refractory Hodgkin lymphoma, certain patient groups, such as elderly patients, and toxicity of first-line treatment still pose significant challenges. Consequently, new treatment options are needed. Recently, many new treatment concepts have been evaluated in clinical trials. Targeted drug-antibody conjugates and immune checkpoint inhibitors have decisively changed treatment approaches. This review aims to give a comprehensive overview of novel agents in Hodgkin lymphoma that have been recently or are currently being evaluated in clinical trials. In addition to dedicated sections on brentuximab vedotin (BV) and immune checkpoint inhibitors, other emerging substances and concepts are discussed. In doing so, this review compares trial results regarding safety and efficacy. A special focus lies on the effect novel agents will have on the different treatment settings faced by clinicians involved in the treatment of Hodgkin lymphoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Borchmann, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-243705
DOI:	10.1080/10428194.2017.1300898
Journal or Publication Title:	Leuk. Lymphoma
Volume:	58
Number:	10
Page Range:	S. 2275 - 2287
Date:	2017
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; CANCER-RELATED FATIGUE; INDUCED KILLER-CELLS; PHASE-II TRIAL; BRENTUXIMAB VEDOTIN; OPEN-LABEL; HEMATOLOGIC MALIGNANCIES; DOSE-ESCALATION; REFRACTORY LYMPHOMA; MONOCLONAL-ANTIBODY Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24370